One of the main challenges of cell therapy development is generating sufficient number of high quality (functional) therapeutic cells in timely fashion. In autologous CAR-T cell therapy, hundreds of millions (1x108) to billions (1x109) of cells are often required for each infusion to patients. Prolonged culture is therefore necessary to achieve sufficient cell production. However, cells tend to undergo senescence, exhaustion, and differentiation in prolonged culture leading to reduction of anti-tumor efficacy. Hence, a robust cell culture system for manufacturing clinical-scaled and functional genetically engineered cells is needed.
GenomeFrontier overcomes this challenge by introducing iCellar™ , a platform composed of proprietary agents and/or gene-modified cells that are designed to enhance cell expansion capacity while maintaining cell quality.